Pro-Dex, Inc. Hits 52-Week Low at $24.22 Amid Market Challenges

Pro-Dex, Inc., a microcap company in the Pharmaceuticals & Biotechnology sector, has reached a new 52-week low of USD 24.22 as of October 13, 2025. This significant decline highlights the stock's recent performance, contrasting sharply with its 52-week high of USD 70.26.
Over the past year, Pro-Dex, Inc. has shown a performance increase of 35.44%, significantly outperforming the S&P 500, which recorded a gain of 13.36%. The company's market capitalization stands at USD 116 million, with a price-to-earnings (P/E) ratio of 16.00.

Despite the recent low, Pro-Dex maintains a return on equity of 21.44%, indicating effective management of shareholder equity. The company's debt-to-equity ratio is relatively low at 0.24, suggesting a conservative approach to leveraging. However, the absence of a dividend yield and a modest annual operating profit growth rate of 8.65% over the last five years may raise questions about its long-term growth prospects.

As the stock navigates these fluctuations, its performance metrics will be closely monitored by market participants.